Mosaic ImmunoEngineering Inc. (CPMV) stock
CPMVOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.33+0.00 (0.00%)
Close on Oct 19, 2026Market cap $2.41MP/E –Yield –
Mosaic ImmunoEngineering operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Mosaic ImmunoEngineering's operating income for the twelve months ending Jun 30, 2026 was -$604.01K. For fiscal 2025 it was -$616.12K.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$616.12K | – |
| FY2024 | Dec 31, 2024 | -$879.66K | – |
| FY2023 | Dec 31, 2023 | -$1.40M | – |
| FY2022 | Dec 31, 2022 | -$2.63M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$156.72K | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$154.80K | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$148.13K | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$144.36K | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$148.85K | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$174.77K | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$150.16K | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$186.43K | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$274.30K | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$268.77K | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$275.62K | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$311.87K | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$352.51K | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$459.77K | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$497.55K | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$517.21K | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$883.73K | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$729.04K | – |
See a number that looks wrong?